Roche test boss says COVID rapid test effectiveness to wane as shots increase
Reuters
Published Mar 23, 2021 11:26AM ET
By Reuters Staff
ZURICH (Reuters) - Rapid COVID-19 tests that have become a key part of nations' COVID-19 detection strategies will grow less effective as more people get vaccinated, Roche diagnostics chief Thomas Schinecker said on Tuesday.
Rapid antigen tests are reasonably accurate in detecting COVID-19 infections, especially compared to the flu, since viral loads in respiratory passageways are higher, Schinecker said on an investor call.
But that will likely change as shots are rolled out and prevent severe infections with high viral loads, he said.
This could drive future COVID-19 testing business to more-accurate molecular, or PCR, testing. Roche has rapid antigen tests, via its South Korean partner SD Biosensor Inc, as well as its own PCR tests that compete with diagnostics from rivals including Abbott Laboratories (NYSE:ABT).
"If you look at flu, actually rapid antigen testing is not the preferred method because the viral load is not so high and then you actually have issues detecting, you get a lot of false negative," Schinecker said. "As people get vaccinated (for COVID-19), rapid antigen testing will become less relevant simply because of the same reason."
Once the pandemic subsides, the new coronavirus is still expected to cause infections for years to come. Schinecker expected the global PCR testing market for COVID-19 to be "a bit bigger" than existing annual flu testing, now in the low single-digit billions of dollars every year.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.